aggregates

NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial

Source Node:
Time Stamp: December 29, 2023 3:07 AM - Modified On: December 29, 2023 - Published By:
Source Cluster:
Republished By Plato

December 29, 2023 - NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient in its Phase 1/2a trial for SNK01, an autologous natural killer (NK) cell therapy. The innovative product, designed for moderate AD, has demonstrated promising results in neuroinflammation and cognitive function during its Phase 1 safety trial. Key Points: SNK01 Efficacy: NKGen's SNK01, a cryopreserved autologous NK cell therapy, showed improvement in neuroinflammation and cognitive function in the Phase 1 dose-escalation safety trial. The therapy boasts enhanced

The Price is Right

Source Node:
Time Stamp: December 27, 2022 4:09 PM - Modified On: December 27, 2022 - Published By:
Source Cluster:
Republished By Plato

This week we dig a little deeper into our rationale and the challenges we’ve faced in developing a new protocol. As we’ve seen this year, borrowing and lending in crypto can be a risky business which is why we’ve taken our time to thoroughly plan and think through the process. Two essential lessons everyone should have learned in 2022 are that leverage is bad and giving away control of your crypto is a recipe for disaster. To ensure neither of these situations occurs with Paribus we’ve followed the safest approach